Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Kabra Drugs Ltd.
Swot
Kabra Drugs Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Kabra Drugs Ltd. has 16 Strengths, 6 Weaknesses, 0 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(16)
Weakness
(6)
Opportunity
(0)
Threats
(0)
Others
(0)
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years - Nifty500
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over 1 Year
PEG lower than Industry PEG
New 52 week high today
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Company with Zero Promoter Pledge
Stock with Low PE (PE < = 10)
New 52 Week High
Stocks Outperforming their Industry Price Change in the Quarter
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of capital to generate profits - RoCE declining in the last 2 years
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Declining profitability: Falling ROCE
